About: Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.54 (+0.85%)
PASG NASDAQ Passage Bio Inc
Passage Bio Inc share price
PASG price activity
Last Price
$3.540
Change (24hr)
0.03 USD (0.85%)
Volume
539
Volume (4w avg)
-
Open
$3.54
Day Range
$3.54 - $3.54
Previous Close
$3.51
Last Trade
05 Nov, 2:30 pm GMT+0
Delayed
05 Nov, 2:30 pm GMT+0
PASG price performance
Delayed
05 Nov, 2:30 pm GMT+0
PASG details
PASG Market Signals